Pharma Capital

Drug developer Redx Pharma appoints Iain Ross as new chairman

He has over 35 years’ experience in the life sciences arena
rsz_shutterstock_178464512_58f85d84a936a.jpg
There will be a new face around the boardroom table

Drug developer Redx Pharma Plc (LON:REDX) said Iain Ross will become the company’s chairman effective May 1.

He has over 35 years’ experience and is currently spearheading the turnaround at AIM-listed e-Therapeutics, where he is also chairman.

Ross has boardroom roles at Biomer Technology, Premier Veterinary Group and ASX-quoted Anatara Lifesciences as well as being a director of Aldershot Town Football Club.

Previous appointments included the chairmanship of Silence Therapeutics, chief executive of Allergy Therapeutics and CEO of Quadrant Healthcare.

Welcoming the new chairman on board, RedX boss Neil Murray said: “His extensive experience in the life science sector makes him the ideal candidate to take on this role.

“I am confident that under his stewardship the company will deliver shareholder value as we transition into a clinical-stage research and development company with a focus on cancer, immunology and infection."

CLICK to receive the Proactive newsletter

Ian_55ae0ddd437b7.jpg
Why Invest In Redx Pharma Plc? Read More Here

Register here to be notified of future REDX Company articles
View full REDX profile

Redx Pharma Plc Timeline

View All

Related Articles

picture of drug research
“The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," Dr John Reader, Sareum's chief scientific officer said.

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.